Anti-PD1 or anti-CTLA4 therapy was initiated 5 days after tumor grafting, fully controlled tumor growth (Figure 2b), while parental Y3.3 tumors were controlled by anti-CTLA4, but not anti-PD1 treatment (Figure 2c). The gene discussed is CTLA4; the disease is neoplasm.